27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
This study projects that the total cost of caring for Americans with Alzheimer's and related dementias will grow enormously over the coming decades, driven by an aging population. 4 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source
A collaborative dementia care program demonstrated significant financial benefit in a managed Medicare population. 4 key findings →
Design: cohort Participants: 242 Evidence: early
Full summary, score breakdown and related studies → Original source Full text may need a subscription
These findings indicate EXT may be more sensitive to Aβ's role in preclinical AD than level and improve targeting of individuals for AD prevention trials. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Early increases in plasma NfL may reflect early white matter microstructural changes prior to dementia in DS. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Glioblastomas (GBM) are incurable central nervous system (CNS) cancers characterized by substantial myeloid cell infiltration. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The gut microbiota and tumor-associated macrophages (TAMs) affect tumor responses to anti-programmed cell death protein 1 (PD-1) immune checkpoint blockade. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
M1/M2 paradigm of macrophage plasticity has existed for decades. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Treatments for neurodegenerative disorders remain rare, but recent FDA approvals, such as lecanemab and aducanumab for Alzheimer disease (MIM: 607822), highlight the importance of the underlying biological mechanisms in driving discovery and creating disease modifying therapies. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
TBI had the highest percentage (37%) compared to other conditions, which may be attributed to the prevalent challenge of cognitive impairment in TBI in addition to physical disability. 5 key findings →
Design: cohort study Participants: 2,285 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Receipt of potentially burdensome hospitalizations and treatments; receipt of postdischarge home and facility care. 5 key findings →
Participants: 659 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The newly diagnosed ADRD and new AChEI users cohorts included 861,727 and 395,319 patients, respectively. 5 key findings →
Design: cohort study Participants: 861,727 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Prior authorization criteria for Federal Drug Administration (FDA) approved immunotherapeutics, among the class of anti-amyloid monoclonal antibodies (mAbs), established by state drug formulary committees, are tailored for adults with late-onset Alzheimer's disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Maintaining driving independence is important for older adults. 2 key findings →
Participants: 230 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Crude new ADRD diagnosis rate ranged from 1.7 to 5.4 per 100 across HRRs. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Large pre-trained models, also known as foundation models (FMs), are trained in a task-agnostic manner on large-scale data and can be adapted to a wide range of downstream tasks by fine-tuning, few-shot, or even zero-shot learning. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research on cognitive impairment (CI) has increasingly focused on the central nervous system, identifying numerous neuronal targets and circuits of relevance for CI pathogenesis and treatment. 1 key finding →
Design: systematic review Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In mild AD patients aged less than 75 years, the mean age-at-diagnosis of AD in APOE4 carriers was reduced by over 6 years in BCHE-K carriers versus noncarriers. 5 key findings →
Participants: 33 Evidence: low
Full summary, score breakdown and related studies → Original source
This study identified the plasma biomarker analytes and assays that most accurately classified amyloid pathology and other AD-related outcomes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
HIGHLIGHTS: Different plasma phosphorylated tau (p-tau) species reflect different pathological processes of Alzheimer's disease (AD), with p-tau231 showing the greatest association with the earliest increases in brain amyloid beta (Aβ) accumulation, while p-tau217 shows greater association with both brain Aβ and early tau pathology, and other p-tau and tau fragment species show greater association with later stages of brain tau pathology. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Digital assessments are effective at identifying at-risk individuals, supporting their utility as low-burden tools for early AD detection and monitoring. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Therapeutic antibodies have been developed to target amyloid-beta (Aβ), and some of these slow the progression of Alzheimer's disease (AD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The emergence of the United States Food and Drug Administration (FDA)-approved amyloid-targeting therapies for Alzheimer's disease challenges clinicians and healthcare providers with a transformative landscape. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
This QSP platform could support clinical practice challenges to optimize real-world treatment paradigms for new and existing amyloid drugs. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Astrocytes are crucial to brain homeostasis, yet their changes along the spatiotemporal progression of Alzheimer's disease (AD) neuropathology remain unexplored. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
As the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →